Pharmaceutical Market Europe • March 2022 • 38-40
APPOINTMENTS
MSD
Ben Lucas
Merck has announced that Ben Lucas has been appointed to the position of managing director of MSD UK and Ireland. Lucas succeeds David Peacock, who has been appointed president of MSD in Asia Pacific. Lucas joins the UK business from his position of managing director at MSD in the Netherlands. Lucas brings leadership and managerial expertise to his new UK role, having joined the company in 1999 and progressed through pharmaceuticals, sales and marketing roles in the earlier part of his career. Lucas has played an instrumental role in building the MSD Oncology Franchise in the UK and Ireland, developing and producing healthcare solutions and providing access for UK patients to innovative new treatments.
Eli Lilly
Cynthia Cardona
Eli Lilly has appointed Cynthia Cardona as its new president of the Lilly Foundation and as its senior director of social impact for the company. As president, Cardona will lead activities to further pursue racial justice, improve educational outcomes for students in need and improve global health outcomes. Having worked for the company since 2001, Cardona brings a wealth of leadership expertise to her new role.
Spark Therapeutics
Ron Philip
Spark Therapeutics has appointed Ron Philip as its new chief executive officer. Philip succeeds the company’s founder and CEO Jeff Marrazzo who will depart on 1 April and will provide leadership across the company in further developing gene therapies. Philip has served the company as its chief operating officer and with over 30 years’ of experience, has also held positions at Merck, Wyeth, Deloitte and Pfizer.
Ixaka
George O’Rourke
Ixaka has appointed George O’Rourke as vice president and general manager of Ixaka France. O’Rourke brings executive pharmaceutical and biotech experience, having served in the role of vice president and general manager of France for Novartis Gene Therapy, leading the launch of Zolgensma – a gene therapy for spinal muscular atrophy. O’Rourke has worked internationally to help teams deliver pioneering therapies.
Enterprise Therapeutics
Niyati Prasad
Enterprise Therapeutics has appointed Niyati Prasad as its new chief medical officer. Prasad will provide leadership on the company’s development strategy for its respiratory programmes through the clinic. With over 20 years’ experience in global clinical programmes involving immunology and rare diseases, Prasad joins after most recently working at GSK as its senior director of clinical development.
Mesoblast
Eric Rose
Mesoblast has appointed Eric Rose as its new chief medical officer. Since 2013, Rose has served as a non-executive director of Mesoblast. He brings an extensive background in clinical development, working with the US Food and Drug Administration (FDA), the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).
Topas Therapeutics
Cristina de Min
Topas Therapeutics has appointed Cristina de Min as its new chief medical officer. Bringing over 25 years of drug development and regulatory approval experience to her new role, de Min will oversee development programmes, including TPM203 for the treatment of pemphigus vulgaris and TPM502 for coeliac disease. de Min spent 11 years working as life cycle leader at Roche.
iOmx Therapeutics
Murray Yule
iOmx Therapeutics has appointed Murray Yule as the company’s new chief medical officer. Yule takes on the role as a board-certified medical oncologist with a strong background in clinical development programmes. With over 20 years' experience, Yule has worked on the FDA approval of Tafasitamab for the treatment of non-Hodgkin lymphoma at MorphoSys.
RevoluGen
Annalisa Jenkins
RevoluGen has appointed Annalisa Jenkins as its new Chair of the Board of Directors. Jenkins has over 30 years' experience in the global industry, specialising in scientific research, genomics, healthcare systems and regulatory approval. Jenkins serves as a board member for various healthcare companies including Cocoon Biotech, Affimed, AoBiome and Phaim Pharma.
Takeda
Gary Dubin
Takeda has announced the appointment of Gary Dubin as the new president of the company’s Global Vaccine Business Unit. Dubin will be moving from his current position as head of global medical office. Having served at the company for over six years, Dubin has gained extensive leadership experience, spearheading the vaccine business medical affairs and policy team. In this position, Dubin assumed responsibility for supervising vaccine safety, medical governance, clinical operations and regulatory affairs. Prior to his work at Takeda, Dubin spent 20 years at GSK’s vaccine branch, serving as the company’s vice president and head of late clinical development. Dubin’s appointment to the role follows the departure of Rajeev Venkayya who joined Takeda in 2012.
Phico Therapeutics
Clive Page
Phico Therapeutics has appointed Clive Page as Chair of its new Scientific Advisory Board. Page is a Professor of Pharmacology and a director of the Sackler Institute of Pulmonary Pharmacology at King’s College London. In 2012, Page received the Royal Society of Biology President’s Medal for outstanding contributions to life sciences and in 2017, he received an OBE for his services to Pharmacology.
Phico Therapeutics
Anne Greenough
Phico Therapeutics has appointed Anne Greenough to its Scientific Advisory Board. Greenough is Professor of Neonatology and Clinical Respiratory Physiology and director of Education and Training at King’s College London. Greenough served as Chair of the National Institute for Health Research (NIHR) Paediatrics Specialty Group and VP of Science and Research, Royal College of Paediatrics and Child Health.
Phico Therapeutics
Andrew Lever
Phico Therapeutics has appointed Andrew Lever to its new Scientific Advisory Board. Lever serves as Professor of Infectious Diseases at the University of Cambridge and as an Honorary Consultant Physician at Cambridge University Hospital Foundation Trust. Appointed as Chair of Infectious Diseases at the University of Cambridge in 2000, Lever has extensive experience serving on advisory committees in the UK and internationally.
Phico Therapeutics
William Hope
Phico Therapeutics has appointed William Hope to its new Scientific Advisory Board. Hope is Chair of AMR Research at the University of Liverpool. Hope provides leadership at the Centre of Excellence in Infectious Diseases Research (CEIDR) which focuses on antimicrobial resistance. Hope brings 30 years of experience in infectious disease, clinical microbiology and antimicrobial drug development to the role.
Phico Therapeutics
Mark Wilcox
Phico Therapeutics has appointed Mark Wilcox to its Scientific Advisory Board. Wilcox serves as Chair of PHE’s Rapid Review Panel for the NHS, alongside his role as a member of PHE’s Programme Board on Healthcare Associated Infection & Antimicrobial Resistance. Wilcox has also worked as an advisor to the UK government throughout the COVID-19 pandemic.
Phico Therapeutics
Frank van Haren
Phico Therapeutics has appointed Frank van Haren to its Scientific Advisory Board. van Haren has worked as a senior intensive care physician and is director of intensive care at the St George Hospital, Australia. He is an international leader and expert in clinical and translational research in intensive care, leading two investigator-initiated collaborative COVID-19 studies.
ProMIS Neurosciences
Guy Rouleau
ProMIS Neurosciences has announced the appointment of Guy Rouleau to its Scientific Advisory Board. Rouleau has over two decades of experience, serving as director of The Neuro (Montreal Neurological Institute-Hospital) Chair of the Department of Neurology and Neurosurgery, McGill University, director of the Department of Neuroscience, McGill University Health Centre.
ProMIS Neurosciences
Alain Dagher
ProMIS Neurosciences has appointed Alain Dagher to its Scientific Advisory Board. Since 1997, Dagher has worked as an attending neurologist at the Montreal Neurological Institute. Dagher specialises in movement disorders with a focus on Parkinson’s Disease. His research has shed light on cognitive issues including anxiety, schizophrenia and drug addiction.
imc group
Sanjay Jariwala
imc group has appointed Sanjay Jariwala as its new CEO, bringing twenty years’ experience in senior leadership positions across medical, business development and corporate strategy. Jariwala worked at SVP Worldwide Medical at Biogen and also served as vice president of strategy coupled with his role as vice president of medical for infection, neuroscience and autoimmunity at AstraZeneca.
OPEN Health
Annemarie Clegg
OPEN Health has appointed Annemarie Clegg as its chief medical officer. Joining in 2018 with Peloton Advantage, Clegg has been integral to building medical consultancy services and promoting US business growth as senior vice president of strategic services. Clegg has over 20 years’ experience in medical communications and will support staff development and strategy.
OPEN Health
Jennifer Chilver
OPEN Health has appointed Jennifer Chilver as its new chief commercial officer. Chilver will oversee the company’s international commercial strategy, marketing and client growth initiatives. Having worked for OPEN Health since 2014, Chilver has proven leadership experience, speaheading a win for the company’s ‘Medical Affairs Agency of the Year’ entry.
Envision Pharma Group
Paul Archer
Envision Pharma Group has appointed Paul Archer as its chief commercial strategy officer. Archer will provide leadership in developing integrated commercial group strategy by implementing new scientific and tech services. Archer has been with the company for over a year and brings 20 years’ of strategic experience and commercial industry knowledge to the position.
Langland
Julia Kirby
Langland has appointed Julia Kirby as its new director of internal engagement and culture. Kirby will support group managing director Victoria Wright with the planning, development and refinement of various agency initiatives. Kirby has a strong background in leadership positions, having served as director at Publicis LifeBrands, as an associate director at Porter Novelli and as an account director and consultant at Edelman.
ONEHealth
Claire Deach
ONEHealth Communications has announced the appointment of Claire Deach in the newly created position of media director. Deach started her career in healthcare publishing with Prescriber and has spent the last 20 years in media buying, recently working with Four Health Media and has worked with a multitude of brands. In her role within the media team, Deach will oversee media planning and buying for various clients.
Four Communications Group
Matt de Gruchy
Four Communications Group has appointed Matt de Gruchy as chief executive of its health branch, Four Health. de Gruchy will be responsible for overseeing a team of over 70 staff, delivering media planning and buying, communications and creative and digital campaigns. Bringing more than 25 years’ experience to the role, de Gruchy has served at Ogilvy Healthworld UK where he worked a seven year tenure as CEO.
IPG Health
Jonathan Kukathasan
IPG Health has appointed Jonathan Kukathasan as its new president of the company’s UK division, overseeing 250 employees in both London and Hampshire. Having served as a member of IPG Health for 17 years, Kukathasan has a proven background in leadership, heading international teams on global and multi-market brands. Kukathasan has also served as president at McCann Health UK since April 2021.
IPG Health
Joerg Hempelmann
IPG Health has appointed Joerg Hempelmann as president for IPG Health Europe division.
Hempelmann will lead the network’s offering across Europe, growing its client partnerships. Hempelmann has a strong
background in leadership, having served as IPG Health’s president for Germany. In 2018, Hempelmann worked at FCB Health, serving as its president for Europe.
IPG Health
Maximilian Lechner
IPG Health has announced its appointment of Maximilian Lechner as its new president of IPG Health for its division in Germany, overseeing around 100 employees. Having worked at IPG Health Germany for over three years, ahead of his new role Lechner has proven leadership experience, being stationed internationally while in charge of managing offices in Frankfurt and Munich.
IPG Health
Philippe Pariente
IPG Health has announced the appointment of Philippe Pariente as its new president of IPG Health, France. Pariente will work alongside Claire Vancappel – managing director – in leading and overseeing around 100 employees. Prior to his work at IPG Health, Pariente was president for McCann Health France from 2006, forming a strong track record of leadership for major pharmaceutical brands.
IPG Health
Loris Marchet
IPG Health has announced the appointment of Loris Marchet as its new president of IPG Health for the company’s division in Spain. Marchet worked at FCB Health Europe as its general manager for Spain and the company’s group management director for Europe. Marchet previously served as a managing partner for Global Healthcare and as client service director for McCANN Health.